How Much Money Did Pfizer Make From Viagra? | Profit Timeline

Daily How Much / By

Pfizer’s Viagra brought in billions over two decades, peaking near $2 billion a year before U.S. generics cut sales sharply.

Viagra launched in 1998 and quickly turned into a blockbuster. The pill passed $1 billion in its second year on shelves and stayed near the top of Pfizer’s portfolio for years. Sales later slid when generics arrived in December 2017 in the U.S., but the brand kept meaningful revenue through 2019 and still appears in select markets after Pfizer’s Upjohn unit combined with Mylan to form Viatris in 2020. Below, you’ll see the clearest, sourced read on what the drug earned and why the curve rose, then fell.

How Much Money Did Pfizer Make From Viagra? Numbers At A Glance

This section gathers landmark figures from company filings and credible reporting. Amounts are rounded to keep them easy to scan; “Global” means worldwide brand revenue for Pfizer unless noted.

Year Or Marker Viagra Revenue (USD) Scope / Source
1999 (Year 2) >$1 billion Global; chart/report notes early surge beyond $1B in second year. Source: Statista overview (worldwide sales since 1998).
2012 >$2 billion Global; “more than $2B worldwide.” Source: AP report carried by AOL on Pfizer–Teva settlement.
2012 ~$1.14 billion U.S.; same AP item notes about $1.14B in U.S. sales prior year.
2013 ~$1.8 billion Global; annual profit tied to Viagra was about $1.8B around 2013. Source: TIME history feature.
2017 $788 million U.S.; last full year before U.S. generics. Source: Arizton/PR Newswire summary.
2018 $217 million U.S.; post-generic entry drop. Source: Arizton/PR Newswire summary.
2019 $497 million Global; Pfizer’s reported Viagra sales for 2019. Source: WallStreetZen stats page citing company data.

Two takeaways jump out: first, the peak period sat near 2012–2013 with global sales around $2 billion; second, the U.S. loss of exclusivity in December 2017 led to a swift step-down in American revenue the very next year.

Taking Viagra In Pfizer’s Revenue Context — The Safe Read

Let’s answer the intent behind the question. If you want a single headline number for the entire life of the brand, Pfizer has never published a formal cumulative tally just for Viagra. Still, with clear annual anchors, a conservative read is possible. The brand clocked more than $1 billion a year soon after launch, ran near the $2 billion mark in its peak phase, and remained in nine-figure territory even after generics.

Stacking those years produces a sensible range: tens of billions in lifetime revenue for Pfizer through 2019, when the company last broke out a clean annual figure pre-Upjohn separation. That range fits the pattern you see with long-lived blockbusters and aligns with reported peaks and late-cycle numbers shown in the table above.

Main Dates That Shaped The Money Curve

The revenue arc tracks three moments: approval, peak, and generic entry. Viagra won U.S. approval in March 1998; you can verify this in the FDA record for sildenafil. Global adoption made it a household name and a steady earner. Then came exclusivity loss and the generic wave. Pfizer’s own 2017 Form 10-K explains that a Teva generic launched in the U.S. in December 2017 under a royalty-bearing deal, which reset pricing and share. You can see that wording in the company’s filing here: Pfizer 2017 Form 10-K.

How Much Money Did Pfizer Make From Viagra? Method, Sources, And Caveats

Pfizer groups brands differently across time, and not every annual report lists a neat product-by-product table for each market. To answer the question in a reader-friendly way, this piece leans on:

  • Pfizer and SEC filings for patent timing and segment notes.
  • Reputable coverage indicating peak and U.S. sales levels around 2012–2013.
  • A 2019 brand-level number that still showed material revenue before Upjohn’s separation.

That mix lets you see both the size of the brand and the turning points that changed its trend.

Close Variant: How Much Pfizer Earned From Viagra Over Time — By The Numbers

Here’s the narrative behind those numbers, tied to real-world events.

Launch To Lift-Off (1998–2003)

Approval hit in March 1998, and prescriptions surged. Reports show Viagra passed $1 billion in its second year on the market, a pace reserved for the top tier of therapies. That early wave set the base for a long revenue run. Source: Statista overview on worldwide sales trend.

Longevity And Peak Years (2004–2013)

The brand kept broad awareness and payer acceptance. Around 2012, worldwide sales topped $2 billion; U.S. sales alone were about $1.14 billion; reporting in 2013 placed annual profit tied to Viagra near $1.8 billion, which aligns with that global sales range. Sources: AP report (AOL), TIME historical feature.

Patent Cliffs, Price Pressure, And Generics (2014–2019)

Method-of-use coverage extended protection for a time, but the U.S. generic deal with Teva led to a December 2017 launch. U.S. revenue fell from about $788 million in 2017 to $217 million in 2018. Yet the brand still posted $497 million globally in 2019 across remaining geographies and channels. Sources: Pfizer 2017 Form 10-K; Arizton/PR Newswire; WallStreetZen 2019 figure.

Where The Brand Sits Now

In November 2020, Pfizer completed the separation of its Upjohn unit and combined it with Mylan to form Viatris, which now manages a large list of legacy brands, including Viagra in many markets. See Pfizer’s press note on the transaction for context.

What The Dollars Mean: Three Practical Reads

1) Viagra Was A Durable Earner

Cross a billion in year two, hover near $2 billion at peak, then hold post-generic share in multiple regions: that pattern marks a classic long-tail brand.

2) U.S. Generics Drove The Sharpest Drop

The 2017 generic entry flipped the pricing dynamic. The next year’s U.S. revenue fell into the low hundreds of millions, a common path when a high-awareness brand meets several lower-priced competitors at once.

3) The Brand Still Mattered After Generics

With nearly half a billion dollars worldwide in 2019, Viagra remained material inside Pfizer right up to the Upjohn separation.

Revenue Milestones And Triggers

Scan the key events that shaped sales. These sit in date order.

Milestone Date Impact On Sales
U.S. FDA Approval Mar 1998 Opened the market; prescriptions spiked. Source: FDA record for sildenafil.
Second-Year Sales Top $1B 1999 Validated blockbuster status; set a high baseline. Source: Statista overview.
Peak Period Near $2B Global 2012–2013 Marked top of the curve; U.S. near $1.14B; profit tied near $1.8B. Sources: AP report; TIME.
Generic Deal And Launch (U.S.) Dec 2017 Teva launch under license; U.S. revenue stepped down in 2018. Source: Pfizer 2017 Form 10-K; Arizton.
Global Brand Still At $497M 2019 Showed enduring demand pre-separation. Source: WallStreetZen stat citing company data.
Upjohn–Mylan Form Viatris Nov 2020 Legacy brands, including Viagra in many markets, moved under Viatris. Source: Pfizer press note.

Guided Estimate: Lifetime Money Earned By Pfizer From Viagra

Because Pfizer does not publish a clean, single cumulative figure, the strongest answer is a grounded range. Using the anchors above—more than $1 billion in the early years, a stretch near $2 billion around 2012–2013, and hundreds of millions even in 2019—the brand generated tens of billions of dollars in revenue for Pfizer across 1998–2019. The curve then shifts as Viatris takes the wheel in many markets after late 2020. If you need a precise lifetime total, the only path is to total each year’s brand line from historical segment reports where available, then adjust for geography changes around the Upjohn separation. Public filings give the timing and the post-2017 mix, but not a full year-by-year global table.

What Drove Demand And Pricing

Brand Recognition

The blue color, the name, and the early ad push created recall most therapies never reach. That helped sustain steady global use over a long arc.

Competition And Substitution

Competitors like Cialis and Levitra added choice and price tension mid-cycle. Generic entry finished the reset, especially in the U.S., where the 2018 revenue drop shows how quickly price and share move once exclusivity ends.

Portfolio Moves

Pfizer’s shift of legacy brands into Upjohn, then Viatris, changed where revenue shows up on a company chart, not whether patients still fill sildenafil. That’s why a brand can stay visible in pharmacy data even as the original owner’s earnings mix evolves.

Bottom Line On Pfizer And Viagra

If you came here asking, How much money did Pfizer make from Viagra? the answer is clear in direction and scale: a blockbuster that earned billions year after year, peaking near $2 billion annually, then settling into a long tail after U.S. generics in late 2017. Exact lifetime dollars are not tallied in a single line by Pfizer, yet the sourced markers above show why any reasonable estimate lands in the tens of billions through 2019, before much of the brand’s footprint moved to Viatris in 2020.

Sources And Verification